MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D
MannKind Corporation announced it has been awarded a grant from Breakthrough T1D to support the INHALE-1ST clinical study evaluating its inhaled insulin product, Afrezza, in pediatric patients newly diagnosed with type 1 diabetes. The study aims to assess safety and efficacy of Afrezza combined with basal insulin in youth aged 10 to under 18. This …